NLRP3 and type 2 diabetes mellitus: Interestingly, glyburide, a sulfonylurea drug extensively used for the treatment of T2D, which inhibits the ATP-dependent potassium (KATP) channel, blocking K+ efflux, has been identified as an NLRP3 inhibitor [89].